Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec 17;10(1):22178.
doi: 10.1038/s41598-020-79252-8.

Impact of intraoperative margin clearance on survival following pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis

Affiliations
Meta-Analysis

Impact of intraoperative margin clearance on survival following pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis

Emrullah Birgin et al. Sci Rep. .

Abstract

The use of intraoperative margin revision to achieve margin clearance in patients undergoing pancreatoduodenectomy for pancreatic cancer is controversial. We performed a systematic review and meta-analysis to summarize the evidence of intraoperative margin revisions of the pancreatic neck and its impact on overall survival (OS). Nine studies with 4501 patients were included. Patient cohort was stratified in an R0R0-group (negative margin on frozen and permanent section), R1R0-group (revised positive margin on frozen section which turned negative on permanent section), and R1R1-group (positive margin on frozen and permanent section despite margin revision). OS was higher in the R1R0-group (HR 0.83, 95% CI 0.72-0.96, P = 0.01) compared to the R1R1-group but lower compared to the R0R0-group (HR 1.20; 95% CI 1.05-1.37, P = 0.008), respectively. Subgroup analyses on the use of different margin clearance definitions confirmed an OS benefit in the R1R0-group compared to the R1R1-group (HR 0.81; 95% CI 0.65-0.99, P = 0.04). In conclusion, intraoperative margin clearance of the pancreatic neck margin is associated with improved OS while residual tumor indicates aggressive tumor biology. Consensus definitions on margin terminologies, clearance, and surgical techniques are required.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
PRISMA flow chart.
Figure 2
Figure 2
Forest plots comparing overall survival (A) in patients with secondary R0 resection after margin revision (R1R0-group) and en bloc R0-resection (R0R0-group), (B) in patients with R0 resection after margin revision (R1R0-group) and residual tumor on final assessment (R1R1-group), and in patients with en bloc R0-resection (R0R0-group) and residual tumor on final assessment (R1R1-group). An inverse variance random effects model was used for meta-analysis. Squares and horizontal bars indicate point estimate (hazard ratios) with 95% CI for the individual studies.
Figure 3
Figure 3
Subgroup analysis with forest plots comparing overall survival by using a 0-mm and 1-mm margin clearance (A) in patients with secondary R0 resection after margin revision (R1R0-group) and en bloc R0-resection (R0R0-group), (B) in patients with R0 resection after margin revision (R1R0-group) and residual tumor on final assessment (R1R1-group), and in patients with en bloc R0-resection (R0R0-group) and residual tumor on final assessment (R1R1-group). An inverse variance random effects model was used for meta-analysis. Squares and horizontal bars indicate point estimate (hazard ratios) with 95% CI for the individual studies.

References

    1. Pereira SP, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 2020 doi: 10.1016/S2468-1253(19)30416-9. - DOI - PMC - PubMed
    1. Adamu M, et al. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology. 2018 doi: 10.1016/j.pan.2018.05.005. - DOI - PubMed
    1. Sinn M, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35:3330–3337. doi: 10.1200/JCO.2017.72.6463. - DOI - PubMed
    1. Kleeff J, et al. Pancreatic cancer. Nat. Rev. Dis. Primers. 2016;2:16022. doi: 10.1038/nrdp.2016.22. - DOI - PubMed
    1. Yang C, et al. Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. Oncotarget. 2017;8:72315–72323. doi: 10.18632/oncotarget.20315. - DOI - PMC - PubMed

Publication types